Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

Phase 1

Completed

• Conditions: Clear Cell Renal Cell Carcinoma; Suspected Recurrent Renal Clear Cell Carcinoma; Recurrent Renal Cell Cancer
• Interventions: Drug: 89Zr-Girentuximab

• Registration Number: NCT05861778
• Lead Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited

Brief Summary

The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission Tomography/Computed Tomography (PET/CT) in adult Chinese patients with indeterminate renal masses or Suspected Recurrent Renal Clear Cell Carcinoma

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-04-05
• Study First Submitted QC: 2023-05-14
• Study First Posted: 2023-05-17
• Study Start: 2023-06-26
• Primary Completion: 2023-11-27
• Study Completion: 2023-11-27
• Status Verified: 2023-12
• Last Update Submitted: 2023-12-07
• Last Update Posted: 2023-12-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1. Voluntarily signed written informed consent
2. Chinese male or female≥18 years old.
3. Have an indeterminate renal mass, suspected renal cell carcinoma, or previously diagnosed ccRCC, suspected recurrence on the pre-screening imaging from Day -90 to Day -1
4. Negative serum pregnancy test for female subjects of childbearing potential at screening. Confirmed negative urine pregnancy test within 24 hours prior to administration of investigational product.
5. Expected survival ≥ 6 months.
6. Agree to follow appropriate and highly effective contraception method for at least 35 days after the administration of 89Zr-TLX250.

Exclusion Criteria

1. Renal mass is known to be a metastasis of another primary tumor.
2. Have other malignancies that require treatment.
3. Planned antineoplastic therapies (for the period between IV administration of 89Zr-TLX250 and imaging).
4. Have received chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to the planned administration of 89Zr-TLX250 or such therapy resulted in a persistent adverse event (> Grade 1) (per National Cancer Institute-Common Toxicity Criteria version 5.0 [NCICTCAE v5.0]).
5. Exposure to murine or chimeric antibodies within the last 5 years.
6. Prior use of radionuclides with an interval of less than 10 halflives.
7. Exposure to any investigational diagnostic or therapeutic agent within the first 4 weeks or 5 half-lives (whichever is longer) of the planned administration of 89Zr-TLX250.
8. Renal insufficiency with glomerular filtration rate (GFR) ≤ 60 mL/min/1.73 m².
9. Uncontrolled psychiatric disorders.
10. Women who are pregnant or breastfeeding.
11. Known hypersensitivity to girentuximab or DFO (deferoxamine).
12. Have a serious non-malignant disease (e.g., infectious disease, autoimmune disease, or metabolic disease) that, in the opinion of the investigator, may interfere with the purpose of the study or subject safety or compliance.
13. Vulnerable population (e.g., being in detention).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
89Zr-girentuximab	89Zr-Girentuximab	A single administration of 37 MBq (+/-10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab

Primary Outcome Measures

Name	Time	Method
Safety parameter Physical Examination	9 days	Frequency of occurrence and severity of abnormal findings in safety investigations regarding the physical examination.
Safety parameter concomitant medications	9 days	Frequency of occurrence and severity of abnormal findings in safety investigations regarding concomitant medications.
Safety parameter Vital Signs	9 days	Frequency of occurrence and severity of abnormal findings in safety investigations regarding the Vital signs
Safety parameter Laboratory examinations	9 days	Frequency of occurrence and severity of abnormal findings in safety investigations regarding Laboratory examinations.
Safety parameter ECG	9 days	Frequency of occurrence and severity of abnormal findings in the 12-lead ECG (ECG QT Interval)

Secondary Outcome Measures

Name	Time	Method
Whole blood radioactivity PK parameters	6 days	This outcome will be measured by analysing the radioactivity present in the blood at baseline (pre-dose), 0.5h, 1h, 2h, 4h, 24h, 72h and Day 5+/-1 day. Assessments include: Cmax (maximum concentration)
Radiation dosimetry	8 days	whole body PET/CT scans will be acquired in supine position at 0.5, 4, 24, 72 and 168±24 h (Day 7±1) post injection, using low dose CT without contrast agent. Normalized Absorbed Dose = Absorbed Dose/ Administered Dose
Tumour dosimetry	Whole body PET/CT scans will be acquired in supine position at 0.5, 4, 24, 72 and 168±24 h (Day 7±1) post injection	Normalised whole body effective radiation dose (mSv/MBq)

Trial Locations

Locations (1)

Peking University Cancer Hospital & Institute; 🇨🇳 Beijing, China